Filtering

Page: () 1 2 3 4 5 6 7 8 9 10 ()
ECCO'17 BarcelonaOP021: Hyperbaric oxygen therapy is safe and effective for hospitalised Ulcerative Colitis patients suffering from moderate- severe flares: A multi-center, randomised, double-blind, sham- controlled trial
Year: 2017
Source: ECCO'17 Barcelona
Authors: Dulai P.
Files: 1
ECCO'17 BarcelonaOP022: Proximity extension assay based proteins show immune cell specificity and can diagnose and predict outcomes in Inflammatory Bowel Diseases: IBD Character study
Year: 2017
Source: ECCO'17 Barcelona
Authors: Kalla R.
Crohn's disease, Ulcerative colitis, Immunology
Files: 1
ECCO'18 ViennaOP022: Rapidity of clinical and laboratory improvements following upadacitinib induction treatment: Data from the CELEST study
Year: 2018
Source: ECCO'18 Vienna
Authors: Schreiber Stefan
Files: 1
ECCO'18 ViennaOP023: A phase 3b open-label multicentre study (VERSIFY) of the efficacy of vedolizumab on endoscopic healing in Moderately to Severely active Crohn’s Disease (CD)
Year: 2018
Source: ECCO'18 Vienna
Authors: Danese Silvio
Files: 1
ECCO'17 BarcelonaOP023: Maintenance of clinical effect in patients with moderate- to-severe Crohn’s Disease treated with filgotinib, a selective JAK1 inhibitor: Exploratory 20-week data analysis of the Phase 2 FITZROY study
Year: 2017
Source: ECCO'17 Barcelona
Authors: Vermeire S.
Filgotinib
Files: 1
ECCO'17 BarcelonaOP024: Childhood-onset Inflammatory Bowel Disease and risk of cancer – a Swedish nationwide cohort study 1964-2014
Year: 2017
Source: ECCO'17 Barcelona
Authors: Olén O.
IBD and malignancy, Lymphoma, Paediatric
Files: 1
ECCO'18 ViennaOP024: Long-term safety and efficacy of the anti-MAdCAM monoclonal antibody SHP647 for the treatment of Crohn’s Disease: The OPERA II study
Year: 2018
Source: ECCO'18 Vienna
Authors: D´Haens Geert R
Files: 1
ECCO'18 ViennaOP025: Comparative effectiveness of vedolizumab and tumour necrosis factor–antagonist therapy in Crohn’s Disease: A multicentre consortium propensity score–matched analysis
Year: 2018
Source: ECCO'18 Vienna
Authors: Dulai Parambir S
Files: 1
ECCO'17 BarcelonaOP025: Evaluation of adalimumab effectiveness in anti-tumor necrosis factor-naïve pediatric patients with Crohn’s Disease in clinical practice
Year: 2017
Source: ECCO'17 Barcelona
Authors: Steiner S.
Crohn's disease, Disease activity Indices, Adalimumab
Files: 1
ECCO'18 ViennaOP026: Comparative effectiveness of vedolizumab and TNF-antagonist therapy in Ulcerative Colitis: A multicentre consortium propensity score–matched analysis
Year: 2018
Source: ECCO'18 Vienna
Authors: Dulai Parambir S
Files: 1
ECCO'17 BarcelonaOP026: Zero diagnostic yield of dysplasia in polyp adjacent biopsies for patients with Inflammatory Bowel Disease
Year: 2017
Source: ECCO'17 Barcelona
Authors: Lahiff C.
Colonoscopic surveillance, Chromoendoscopy, Colonoscopy, Dysplasia, UC colorectal cancer surveillance
Files: 1
ECCO'17 BarcelonaOP027: IL-33/ST2 axis sustains gut mucosal wound healing and cancerogenesis in Colitis-associated colorectal cancer
Year: 2017
Source: ECCO'17 Barcelona
Authors: Lopetuso L.
Epithelial cell, Fibroblast, Immunology
Files: 1
ECCO'18 ViennaOP027: SUCNR1 receptor mediates intestinal fibrosis
Year: 2018
Source: ECCO'18 Vienna
Authors: Cosin-Roger Jesus
Files: 1
ECCO'17 BarcelonaOP028: Gut specific regulatory T cells – a new frontier for Crohn’s Disease therapy
Year: 2017
Source: ECCO'17 Barcelona
Authors: Goldberg R.
Immunology, Lymphocyte,T Cell
Files: 1
ECCO'17 BarcelonaOP029: Hypoacetylation of histone-3 is a hallmark of intestinal fibrosis in Crohn’s Disease
Year: 2017
Source: ECCO'17 Barcelona
Authors: Lewis A.
Genetic factors, Fibrosis
Files: 1
ECCO'17 BarcelonaOP030: Identification of disease-relevant bacterial signatures in gnotobiotic IL-10 deficient mice using fecal samples from IBD patients undergoing hematopoietic stem cell transplantation
Year: 2017
Source: ECCO'17 Barcelona
Authors: Metwaly A.
Immunology, Microbiota, HSCT
Files: 1
ECCO'18 ViennaOP031: Clinical effectiveness, safety and immunogenicity of anti-TNF therapy in Crohn’s Disease: 12 month data from the PANTS study
Year: 2018
Source: ECCO'18 Vienna
Authors: Kennedy Nicholas A
Files: 1
ECCO'17 BarcelonaOP031: Long-term safety and tolerability of oral tofacitinib in patients with Crohn’s Disease: Results from a phase 2 open-label 48-week extension study
Year: 2017
Source: ECCO'17 Barcelona
Authors: Panés J.
Tofacitinib, Crohn's Disease
Files: 1
ECCO'17 BarcelonaOP032: Efficacy and safety of oral tofacitinib as maintenance therapy in patients with Moderate to Severe Ulcerative Colitis: Results from a phase 3 randomised controlled trial
Year: 2017
Source: ECCO'17 Barcelona
Authors: Panés J.
Tofacitinib, Ulcerative Colitis
Files: 1
ECCO'18 ViennaOP032: Outcome of pregnancies in female IBD patients treated with vedolizumab
Year: 2018
Source: ECCO'18 Vienna
Authors: Moens Annick
Files: 1
Page: () 1 2 3 4 5 6 7 8 9 10 ()